Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-8-11
|
pubmed:abstractText |
U-54494A, a racemic mixture of two enantiomers, is being developed in racemic form as an anticonvulsant drug candidate. A comparative pharmacokinetic study with intravenous and oral administration of the two individual enantiomers to the dog was conducted to evaluate the potential enantioselective pharmacokinetics of U-54494. Following i.v. administration, the (-)- and (+)-enantiomers showed no significant differences in plasma clearance (0.84 +/- 0.11 versus 0.86 +/- 0.06 l/hr/kg) and terminal elimination half-life (11.2 +/- 2.7 versus 8.0 +/- 2.6 hr) for the parent drug. However, the AUC of intact drug was two-fold lower with two-fold shorter elimination half-life following the oral administration for the (+)-enantiomer as compared to the (-)-enantiomer. Higher plasma levels of the four metabolites were also observed for the (+)-than for the (-)-enantiomer, particularly after oral administration. These results suggested that the (+)-enantiomer appeared to be more extensively metabolized by first-pass effect than the (-)-enantiomer after oral dosing, and as a result, oral bioavailability for the (+)-enantiomer is only one half of that for its antipode (12.0 +/- 1.5% versus 26 +/- 9%).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1024-2430
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
89-96
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9676281-Administration, Oral,
pubmed-meshheading:9676281-Animals,
pubmed-meshheading:9676281-Anticonvulsants,
pubmed-meshheading:9676281-Area Under Curve,
pubmed-meshheading:9676281-Biological Availability,
pubmed-meshheading:9676281-Chromatography, High Pressure Liquid,
pubmed-meshheading:9676281-Dogs,
pubmed-meshheading:9676281-Female,
pubmed-meshheading:9676281-Half-Life,
pubmed-meshheading:9676281-Injections, Intravenous,
pubmed-meshheading:9676281-Male,
pubmed-meshheading:9676281-Pyrrolidines,
pubmed-meshheading:9676281-Rats,
pubmed-meshheading:9676281-Stereoisomerism
|
pubmed:year |
1996
|
pubmed:articleTitle |
Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog.
|
pubmed:affiliation |
Upjohn Laboratories, Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001, USA. wzhong@pwinet.upj.com
|
pubmed:publicationType |
Journal Article,
Comparative Study
|